- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-811X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
New bortezomib-based combination therapy for elimination of myeloma cells ; volume:7 ; number:1 ; day:26 ; month:2 ; year:2009 ; pages:1 ; date:12.2009
Cell communication and signaling ; 7, Heft 1 (26.2.2009), 1, 12.2009
- Urheber
-
Meister, S.
- Beteiligte Personen und Organisationen
-
Lang, V.
Wissniowski, TT
Voll, RE
SpringerLink (Online service)
- DOI
-
10.1186/1478-811X-7-S1-A34
- URN
-
urn:nbn:de:1111-201607265424
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Meister, S.
- Lang, V.
- Wissniowski, TT
- Voll, RE
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
A feline case of multiple myeloma treated with bortezomib
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Bortezomib
Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
A feline case of multiple myeloma treated with bortezomib
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Bortezomib
Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
A feline case of multiple myeloma treated with bortezomib
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Bortezomib
Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL